Possibilities of using Nolodatak (flupirtine) in the treatment of musculoskeletal pain syndromes


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

There is a high prevalence of musculoskeletal pain syndromes that are associated with long-term disability, worse quality of life in patients, and considerable material costs of treatment and rehabilitation; in addition, undesirable side effects can occur during pharmacotherapy. The paper considers whether Nolodatak (flupirtine) that has an analgesic, muscle relaxant, and neuroprotective effect may be used.

全文:

受限制的访问

作者简介

O. Badalyan

N.I. Pirogov Russian National Research Medical University

Email: nevrcao@gmail.com

S. Burd

N.I. Pirogov Russian National Research Medical University

Email: nevrcao@gmail.com

A. Lebedeva

N.I. Pirogov Russian National Research Medical University

Email: nevrcao@gmail.com

参考

  1. Вознесенская Т.Г. В кн.: Болевые синдромы в неврологической практике. Под ред. А.М. Вейна / М.: МЕДпресс, 1999; 217-84.
  2. Камчатнов П.Р., Батышева Т.Т., Ганжула П.А. и др. Применение катадолона у больных со спондилогенной дорсопатией // Журн. неврол. и психиат. им. С.С. Корсакова. - 2006; 106 (11): 46-9.
  3. Насонов Е.Л., Насонова В.А. Ревматология / М.: ГЭОТАР-Медиа, 2005.
  4. Насонов Е.Л., Лазебник Л.Б., Кукушкин М.Л. и др. Применение нестероидных противовоспалительных препаратов / М.: ИМА-пресс, 2009.
  5. Каратеев А.Е., Насонова В.А. Развитие и рецидивирование язв желудка и двенадцатиперстной кишки у больных, принимающих нестероидные противовоспалительные препараты: влияние стандартных факторов риска // Тер. арх. - 2008; 80 (5): 62-6.
  6. Баранцевич Е., Андреев В. Возможности лечения хронической боли при пояснично-крестцовой радикулопатии // Врач. - 2012; 11: 13-9.
  7. Насонов Е.Л., Яхно Н.Н., Каратеев А.Е. и др. Общие принципы лечения скелетно-мышечной боли. Междисциплинарный консенсус // Научно-практ. ревматол. - 2016; 54 (3): 247-65.
  8. Есин Р.Г., Лотфуллина Н.З., Есин О.Р. Цервикалгия, дорзалгия, люмбалгия. Дифференциальная диагностика, дифференцированная терапия / Казань: ИИЦ УД Президента РТ, 2015.
  9. Banerjee M., Bhattacharyya K. et al. Comparative study of efficacy and tolerability of flupirtine v.s. tramadol in non-steroidal anti-inflammatory drug intolerant mechanical low back pain // Ind. J. Rheumatol. - 2012; 7 (3): 135-40.
  10. Ueberall A., Eberhardt A., Mueller-Schwefe H. Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice // Int. J. Gen Med. - 2016; 9: 39-51.
  11. Qaseem A., Wilt T., McLean R. et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians // Ann. Intern. Med. - 2017; 166 (7): 514-30. doi: 10.7326/M16-2367.
  12. Brown D., Passmore G. Neural KCNQ (Kv7) channels // Br. J. Pharmacol. -2009; 156 (8): 1185-95.
  13. Rivera-Arconada I., Vicente-Baz J., Lopez-Garcia J. Targeting Kv7 channels in pain pathways // Oncotarget. - 2017; 8: 1254-5. doi: 10.18632/oncotarget.15261.
  14. Szelenyi I. Flupirtine, a rediscovered drug, revisited // Inflamm. Res. - 2013; 62 (3): 251-8.
  15. Fleckenstein J., Sittl R., Averbeck B. et al. Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial // J. Transl. Med. - 2013; 11: 34-9.
  16. Kornhuber J., Bleich S., Wiltfang J. et al. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels // J. Neural. Transm. - 1999; 106 (9-10): 857-67.
  17. Klinger F., Bajric M., Salzer I. et al. d-Subunit-containing GABAA receptors are preferred tar-gets for the centrally acting analgesic flupirtine // Br. J. Pharmacol. - 2015; 172 (20): 4946-58.
  18. Klinger F., Geier P., Dorostkar M. et al. Concomitant facilitation of GABAA receptors and KV7 channels by the non-opioid analgesic flupirtine // Br. J. Pharmacol. - 2012; 166: 1631-42.
  19. Harish S., Bhuvana K., Bengalorkar M. et al. Flupirtine: Clinical pharmacology // J. Anaesthesiol. Clin. Pharmacol. - 2012; 28 (2): 172-7.
  20. Klawe C., Maschke M. Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound // Expert Opin. Pharmacother. - 2009; 10 (9): 1495-500.
  21. Bientinesi R., Mancuso C., Martire M. et al. KV7 channels in the human detrusor: channel modulator effects and gene and protein expression // Naunyn Schmiedebergs Arch. Pharmacol. - 2017; 390 (2): 127-37.
  22. Takagi H., Hashitani H. Effects of K+-channel openers on spontaneous action potentials in detrusor smooth muscle of the guinea-pig urinary bladder // Eur. J. Pharmacol. - 2016; 789: 179-86.
  23. Ahuja V., Mitra S., Kazal S. et al. Comparison of analgesic efficacy of flupirtine maleate and ibuprofen in gynaecological ambulatory surgeries: A randomized controlled trial // Indian J. Anaesth. - 2015; 59 (7): 411-5.
  24. Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tense-ness. Results of a postmarket surveillance study // Fortschr. Med. Orig. - 2003; 121 (1): 11-8.
  25. Sampath D., Valdez R., White A. et al. Anticonvulsant effect of flupirtine in an animal model of neonatal hypoxic-ischemic encephalopathy // Neuropharmacology. -2017; 123: 126-35 doi: 10.1016/j.neuropharm.2017.06.002.
  26. Sattler M., Williams S., Neusch C. et al. Flupirtine as Neuroprotective AddOn Therapy in Autoimmune Optic Neuritis // Am. J. Pathol. - 2008; 173 (5): 1496-507.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##